InsidersTradesSigma
Veeva Systems INC Stock: price and insider trades · United States · SEC (Form 4)
Track the Veeva Systems INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Veeva Systems INC has logged 573 insider filings. Market capitalisation: €31.3bn. The latest transaction was filed on 3 June 2026 (Levée d'options). Among the most active insiders: Cabral Timothy S. The full history is accessible without an account.
573
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€21m
126 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Veeva Systems INC Buy (bullish), based on 27 analysts. Average price target: US$244.59.
38Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 6,389 of 25,451 companies
64.3
score / 100
Value42
Quality87
FCF yld4.5%
Earn yld2.9%
EV/EBITDA32.9x
ROE14%
Gross mgn76%
Net mgn28%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 3 June 2026
Declarations573 total
262 shares0Class A Common StockSEC:0001628280-26-040405:0
271 shares0Class A Common StockSEC:0001628280-26-040400:0
750 shares@ US$155.640.0004% mcap25.1% of flowClass A Common StockSEC:0001628280-26-029800:0
750 shares@ US$155.640.0004% mcap25.1% of flowClass A Common StockSEC:0001628280-26-029800
750 shares@ US$153.500.0004% mcap24.9% of flowClass A Common StockSEC:0001628280-26-025087:0
750 shares@ US$153.500.0004% mcap24.9% of flowClass A Common StockSEC:0001628280-26-025087
1,000 shares@ US$231.4350.0% of flowClass A Common StockSEC:0001628280-26-002206
1,000 shares@ US$231.430.0008% mcap50.0% of flowClass A Common StockSEC:0001628280-26-002206:0
720 shares@ US$298.1250.0% of flowClass A Common StockSEC:0001628280-25-044578
720 shares@ US$298.120.0007% mcap50.0% of flowClass A Common StockSEC:0001628280-25-044578:0
2,043 shares0Class A Common StockSEC:0001628280-25-044094
1,226 shares0Class A Common StockSEC:0001628280-25-044088
2,043 shares0Class A Common StockSEC:0001628280-25-044094:0
1,226 shares0Class A Common StockSEC:0001628280-25-044088:0
833 shares@ US$236.718.6% of flowClass A Common StockSEC:0001628280-25-022210:0
802 shares@ US$220.761911.4% of flowClass A Common StockSEC:0001628280-25-017876:0
380 shares@ US$210.94145.2% of flowClass A Common StockSEC:0001628280-25-017504:0
3,882 shares@ US$216.837.0% of flowClass A Common StockSEC:0001628280-25-017092:0
1,120 shares0Class A Common StockSEC:0001628280-25-016287:0
1,324 shares0Class A Common StockSEC:0001628280-25-016298:0
204 shares0Class A Common StockSEC:0001628280-25-016285:0
1,909 shares0Class A Common StockSEC:0001628280-25-016292:0
823 shares0Class A Common StockSEC:0001628280-25-016295:0
500,000 shares0Class A Common StockSEC:0001628280-25-012780:0
328 shares0Class A Common StockSEC:0001628280-25-009559:0
25 of 573 declarations
About Veeva Systems INC
Veeva Systems Inc. is a U.S.-based enterprise software company focused on cloud software, data, artificial intelligence, and consulting for the global life sciences industry. The company is listed in the United States on the NYSE under the ticker VEEV. It was founded in 2007, and its headquarters are in Pleasanton, California, United States. Veeva’s business model is built around a vertical industry platform designed for the operational, regulatory, and commercial needs of pharmaceuticals, biotechnology companies, and other highly regulated life sciences organizations. Its core product stack spans Vault Platform, Vault CRM, Veeva Quality Cloud, Veeva Clinical, Veeva Regulatory, Veeva Safety, Veeva Medical, Veeva Commercial Cloud, and Veeva Data Cloud. More recently, the company has been pushing Veeva AI, a set of domain-specific AI capabilities and agents intended to work deeply inside Veeva applications. This is strategically important because Veeva is not selling generic software; it is offering workflow-heavy, compliance-aware applications tailored to the life sciences value chain. From a competitive standpoint, Veeva holds a leading position in vertical cloud software for life sciences. Its moat is driven by industry specialization, long customer relationships, recurring subscription revenues, and the breadth of its platform, which extends from R&D and clinical operations to quality, regulatory, medical affairs, and commercial execution. In recent corporate communications, Veeva has highlighted the expansion of Vault CRM, growing adoption of Veeva Basics by emerging biotechs, and early momentum around AI-enabled products. That combination reinforces the company’s reputation as a mission-critical vendor rather than a discretionary IT provider. Geographically, Veeva serves customers globally, with a commercial footprint and support capabilities across multiple regions, while maintaining its corporate base in California. Recent notable developments include the rollout of Veeva AI Agents across applications, new biotech-focused product introductions, collaboration announcements related to clinical-trial innovation, and strong quarterly results in 2025 and early 2026, supported by solid subscription revenue growth. For investors, Veeva stands out as a high-quality growth name in the Health & Pharma sector, with exposure to a structurally resilient end market and a differentiated software franchise built on deep domain expertise.
